Why This Question Persists in Clinical Practice

Few questions in pediatric psychopharmacology have lagged behind the evidence as persistently as this one. Twenty years after the TACT trial and a decade after the Cohen meta-analysis, I continue to hear from families that a previous clinician — pediatrician, psychiatrist, or neurologist — refused to prescribe a stimulant because the child also has tics. The treatment-naive child sitting across from me has untreated ADHD that is causing real academic and functional impairment, and a tic disorder that is often mild and not the source of the family's distress. The reasoning offered for withholding stimulant treatment is almost always some version of the original FDA labeling language about contraindication in Tourette syndrome, a labeling decision that predates the modern evidence base by decades.

This article is meant to be unambiguous on this point: in 2026, the default approach to a child or adolescent with ADHD plus tics is to treat the ADHD with whichever medication best fits the clinical picture — including stimulants — and to monitor tics as one of several parameters during titration. Stimulants are no more excluded by the presence of tics than antihypertensives are excluded by the presence of comorbid arthritis. The two conditions coexist; both can be treated; the data do not show that treating one routinely worsens the other.

What follows is the evidence behind that position, the modern guideline landscape, and the clinical framework I use when a family arrives with this question.

The Historical "Contraindication" and Where It Came From

The clinical lore that stimulants worsen tics did not emerge from a single rigorous trial. It accumulated from three converging sources over the 1970s and 1980s.

Early case reports. Beginning in the 1970s, individual case reports described children who developed motor or vocal tics after starting methylphenidate or dextroamphetamine. Some described worsening of pre-existing tics with stimulant dose escalation. Case reports are hypothesis-generating, not hypothesis-testing — they cannot distinguish drug-induced phenomena from temporal coincidence, particularly for a condition like tic disorder that has its peak onset between ages 4 and 8, overlapping with the typical age range for ADHD diagnosis and treatment. But the reports were striking and entered clinical teaching.

Dopaminergic hypothesis logic. Tics, particularly in Tourette syndrome, were and are conceptualized as involving dysregulation of basal ganglia dopaminergic circuits. Antipsychotic medications that block dopamine D2 receptors (haloperidol, pimozide, later aripiprazole and risperidone) reduce tic frequency, supporting the dopaminergic model. Stimulant medications, by contrast, increase synaptic dopamine availability in striatal and prefrontal regions. The mechanistic syllogism was straightforward: if blocking dopamine reduces tics, then increasing dopamine should worsen them. The syllogism is plausible. It also turns out, empirically, to be wrong as a clinical generalization — likely because the specific regional and receptor-subtype effects of low-dose oral stimulants on basal ganglia dopaminergic signaling are far more nuanced than the simple model predicted.

FDA labeling history. The package inserts for methylphenidate and amphetamine products historically carried language listing Tourette syndrome or a family history of Tourette syndrome as a contraindication or warning. This labeling, which entered FDA documents in the late 1970s and 1980s, was the natural artifact of the case-report and mechanistic landscape of that era. It then became self-perpetuating: clinicians read the label, taught the label, and were reluctant to deviate from the label even as the trial evidence accumulated against it. Subsequent FDA labeling revisions softened this language, but the original phrasing persists in the clinical memory of many practitioners trained before approximately 2005.

The historical contraindication, in short, was a reasonable inference from limited data, ossified into a label, and then survived as teaching long past its empirical expiration date.

The Cohen 2015 Meta-Analysis: The Single Most Important Citation

The definitive synthesis of the stimulant-and-tics literature is Cohen SC, Mulqueen JM, Ferracioli-Oda E, et al. "Meta-Analysis: Risk of Tics Associated With Psychostimulant Use in Randomized, Placebo-Controlled Trials." Journal of the American Academy of Child and Adolescent Psychiatry. 2015;54(9):728-736.

The Cohen meta-analysis pooled 22 randomized, placebo-controlled trials of stimulant medication that reported tic data, including more than 2,000 children with ADHD. The primary analyses asked two questions:

  1. In children with ADHD and pre-existing tic disorders, does stimulant treatment worsen tic severity compared with placebo?
  2. In children with ADHD and no pre-existing tic disorder, does stimulant treatment increase the incidence of new-onset tics compared with placebo?

The findings, briefly:

This meta-analysis did what individual trials could not: by pooling across studies, it had statistical power to detect a clinically meaningful effect if one existed. None was found. The Cohen paper is, in my view, the single most important reference for any clinician making decisions about ADHD pharmacotherapy in the context of tics. It is the citation I provide most frequently to families who arrive having been told that stimulants are off-limits.

The TACT Trial: Methylphenidate Plus Clonidine for ADHD With Tics

The Tourette's Syndrome Study Group's Treatment of ADHD in Children with Tics trial — the TACT trial — was published in Neurology in 2002 (Tourette's Syndrome Study Group. "Treatment of ADHD in children with tics: a randomized controlled trial." Neurology. 2002;58(4):527-536) and remains the most-cited single trial on this topic.

TACT was a 16-week, four-arm, randomized, double-blind trial in 136 children with ADHD plus a chronic tic disorder (Tourette syndrome or chronic motor/vocal tic disorder). The four arms were:

  1. Clonidine alone
  2. Methylphenidate alone
  3. Clonidine plus methylphenidate
  4. Placebo

The primary outcomes were ADHD symptom severity (Conners Abbreviated Symptom Questionnaire) and tic severity (Yale Global Tic Severity Scale, YGTSS).

The key findings were striking and have shaped clinical practice ever since:

Treatment Arm ADHD Symptom Effect Tic Effect Clinical Implication
Methylphenidate alone Significant ADHD improvement vs. placebo No worsening of tics vs. placebo Stimulants safe and effective for ADHD in tic patients
Clonidine alone Modest ADHD improvement vs. placebo Significant tic improvement vs. placebo Alpha-2 agonist useful when tics dominate
Combination (MPH + clonidine) Greatest ADHD improvement of any arm Tic improvement comparable to clonidine alone Best overall outcome for ADHD + tics
Placebo Reference Reference Tics fluctuate without medication; baseline waxing-waning

Three implications of the TACT trial are clinically load-bearing:

First, methylphenidate monotherapy did not worsen tics relative to placebo in children with pre-existing tic disorders — an empirical refutation of the historical contraindication, in the exact patient population that contraindication was meant to protect.

Second, the combination of methylphenidate plus clonidine produced the largest gains across both symptom domains. This finding is the basis for the modern combination-treatment approach in ADHD-plus-tics: a stimulant for ADHD plus an alpha-2 agonist for tics is not just additive in symptom coverage, it appears to be synergistic in functional outcome.

Third, clonidine alone produced meaningful tic improvement, supporting the role of alpha-2 agonists as tic-specific agents when the ADHD piece is less prominent.

TACT was a relatively modest single trial in size, and subsequent literature has both replicated its core findings and extended them with guanfacine (which has a somewhat different alpha-2A selectivity profile than clonidine and is widely used as a once-daily extended-release formulation, guanfacine ER). But TACT remains the foundational randomized evidence.

Modern Guidelines: ESSTS, AACAP, and AAN

The current guideline landscape reflects the post-Cohen, post-TACT consensus.

European Society for the Study of Tourette Syndrome (ESSTS). The ESSTS guidelines, developed by Roessner and colleagues and updated across multiple iterations in European Child and Adolescent Psychiatry, explicitly endorse stimulants as appropriate first-line treatment for ADHD in patients with comorbid tic disorders. The guidelines note that the historical contraindication is not supported by current evidence and that withholding stimulants on this basis is not recommended. Alpha-2 agonists (clonidine, guanfacine) are recommended as alternatives or adjuncts, particularly when tics are themselves impairing. The ESSTS guidelines also detail the role of behavioral therapy (CBIT) and antipsychotics for severe tic presentations.

American Academy of Child and Adolescent Psychiatry (AACAP). The AACAP Practice Parameter for ADHD and related practice parameters for tic disorders take a parallel position: stimulants are appropriate for ADHD in the context of tics, with shared decision-making about whether to start with a stimulant or with an alpha-2 agonist depending on the relative severity of the two conditions. The AACAP guidance specifically addresses the historical contraindication and updates it.

American Academy of Neurology (AAN). The AAN practice guideline on the treatment of tic disorders (Pringsheim and colleagues, Neurology 2019) similarly does not contraindicate stimulants in patients with comorbid ADHD and tics. The AAN guideline emphasizes CBIT as a first-line evidence-based behavioral intervention, supports alpha-2 agonists for both ADHD and tic management, and recognizes stimulants as appropriate for the ADHD component of a comorbid presentation.

The convergence across guideline bodies — pediatric neurology, child psychiatry, and a European multidisciplinary society — is significant. Guidelines lag evidence; the fact that these three groups, working from different professional traditions, arrived at the same conclusion is a reasonable proxy for how settled the underlying evidence has become.

Comorbidity Epidemiology: How Often These Conditions Co-Occur

Understanding the prevalence of ADHD-plus-tics is important because it shapes how often the clinical question arises and how high the stakes of getting it right are.

Population Comorbidity Prevalence Source / Note
ADHD in children with Tourette syndrome ~50-60% Across multiple Tourette cohorts and registries; ADHD is the single most common psychiatric comorbidity in Tourette
ADHD in children with chronic tic disorder (CTD) ~30-50% Lower than in full Tourette but still elevated above general population baseline
Tics in general pediatric ADHD samples ~10-20% for any tics; lower for chronic tic disorder/Tourette Transient tics are common in school-age children; chronic tics are less common but enriched in ADHD samples
Tourette syndrome general population prevalence ~0.3-1.0% in school-age children Estimates vary by case-finding methodology
OCD in Tourette + ADHD ~30-40% The "Tourette Plus" presentation — Tourette + ADHD + OCD — is common enough to warrant explicit screening

The high rate of ADHD in Tourette samples (and the reverse) reflects shared neurodevelopmental and genetic substrate. Genome-wide studies have shown meaningful genetic correlation between ADHD, Tourette syndrome, and OCD. This is not three separate conditions that happen to co-occur by chance; it is a partially shared underlying biology that produces overlapping clinical syndromes. The clinical implication is that any child presenting with one of these three conditions should be screened for the other two. For more on the genetic architecture, see my review of ADHD genetics and heritability.

Non-Stimulant Options: Guanfacine, Clonidine, Atomoxetine

Stimulants are not the only option for ADHD in patients with tics, and there are clinical situations where non-stimulants are preferable as first-line. The three non-stimulant agents with the most relevant evidence are alpha-2 agonists (guanfacine and clonidine) and the selective norepinephrine reuptake inhibitor atomoxetine.

Guanfacine and Clonidine (Alpha-2 Agonists)

Alpha-2 adrenergic agonists were originally developed as antihypertensives. Their utility in pediatric ADHD and tic management was discovered subsequently. Both guanfacine and clonidine are available in immediate-release and extended-release formulations; the extended-release products (guanfacine ER, clonidine ER) are FDA-approved for pediatric ADHD as monotherapy and as adjuncts to stimulants.

The mechanism of action involves stimulation of postsynaptic alpha-2A adrenergic receptors in the prefrontal cortex, which enhances signal-to-noise in attention networks. Guanfacine is more selective for the alpha-2A subtype, which is associated with the prefrontal cognitive effect; clonidine is less selective and produces more sedation and hypotensive effects.

For ADHD-plus-tics, alpha-2 agonists are particularly attractive because they treat both conditions through their own mechanism — independent of any concerns about stimulant effects on tics. The TACT trial established clonidine's efficacy for both ADHD and tic symptoms. Subsequent guanfacine trials extended the evidence to that agent. In clinical practice, guanfacine ER is often chosen for daytime ADHD with mild-to-moderate tics; clonidine (often dosed at bedtime to leverage its sedative effect for sleep onset) is often chosen when sleep difficulties or evening tic exacerbations are part of the picture.

Side effects of alpha-2 agonists include sedation (especially with clonidine), dry mouth, orthostatic hypotension, and bradycardia. Abrupt discontinuation can produce rebound hypertension; alpha-2 agonists should be tapered, not stopped abruptly.

Atomoxetine

Atomoxetine is a selective norepinephrine reuptake inhibitor approved for ADHD across the pediatric and adult age range. Its evidence base in the ADHD-plus-tics population is smaller than the stimulant or alpha-2 literature but is favorable. Controlled studies in children with ADHD and tic disorders have shown that atomoxetine improves ADHD symptoms without worsening tic severity, and in some analyses with modest tic improvement.

Atomoxetine is a non-controlled medication, which is sometimes preferred by families concerned about controlled-substance status. Its ADHD effect size is somewhat smaller than stimulants in head-to-head comparisons and its onset is gradual (typically four to eight weeks for full effect). Side effects include gastrointestinal upset, decreased appetite, mood lability in some patients, and rare hepatotoxicity warranting baseline awareness. For the patient with ADHD plus tics who is either stimulant-intolerant or stimulant-averse, atomoxetine is a reasonable evidence-based option. For broader discussion of medication options, see the ADHD medication guide and new ADHD medications in 2026.

Antipsychotics for Tic-Predominant Cases

When tics are themselves severely impairing — interfering with school, causing pain or injury, or producing social isolation — antipsychotic medications are sometimes added or used in place of alpha-2 agonists. Aripiprazole and risperidone have the most pediatric evidence among the second-generation antipsychotics for tic suppression; haloperidol and pimozide have historical FDA approval but are now used less commonly given the metabolic and motor side effect profile of typical antipsychotics. Antipsychotics are not first-line for ADHD-plus-tics; they are reserved for tic-predominant presentations where milder agents have proven insufficient.

Clinical Decision Framework: When and How to Prescribe

The clinical decision is rarely binary. It is a question of which agent to start, in what order, with what monitoring. The framework I use is approximately as follows.

Step 1: Determine the dominant impairment. Is the ADHD or the tic disorder producing more functional impairment? In most pediatric presentations of ADHD-plus-tics, the ADHD dominates: academic underperformance, executive dysfunction, social difficulties, and emotional dysregulation are typically more impairing than the tics themselves. In tic-predominant presentations — severe motor or vocal tics interfering with schooling or social functioning — the tic disorder may be the leading clinical target.

Step 2: For ADHD-predominant presentations, start with an evidence-based ADHD treatment matched to the patient. A stimulant is reasonable as first-line. There is no requirement to start with a non-stimulant solely because the patient also has tics. The Cohen 2015 data and the TACT data are the basis for this default. Choice between methylphenidate-class and amphetamine-class stimulants follows the same considerations as in any ADHD treatment decision: prior response, family history of response, side effect profile, formulation needs (long-acting versus short-acting), and patient preference.

Step 3: For tic-predominant presentations, start with an alpha-2 agonist. Guanfacine ER or clonidine ER provides ADHD symptom benefit while also addressing the tic component through a unified mechanism. If ADHD symptoms remain insufficiently controlled, a stimulant can be added; this is the TACT-style combination approach.

Step 4: Monitor both domains during titration. Tic frequency and severity should be tracked alongside ADHD symptoms during dose adjustment. The Yale Global Tic Severity Scale is the standard research instrument but is not necessary for clinical use; a brief weekly check-in on tic frequency, duration, severity, and family-rated impairment is generally sufficient. Importantly, tics fluctuate naturalistically, with weeks of waxing followed by weeks of waning. Attributing every fluctuation to medication is a common clinical error.

Step 5: If tics emerge or worsen on a stimulant, consider the differential. Options include: continue and observe for spontaneous resolution (often the right answer for mild worsening), reduce dose, switch stimulant class (some individual patients respond differently to methylphenidate versus amphetamine), add an alpha-2 agonist for combined coverage, or transition to atomoxetine. Complete stimulant discontinuation is the least common appropriate response and should not be the reflexive default. The harms of untreated ADHD are themselves substantial — for the broader picture, see my analysis of adverse outcomes of untreated ADHD and the natural course of ADHD pharmacology.

Step 6: Consider behavioral therapy in parallel. Comprehensive Behavioral Intervention for Tics (CBIT) is evidence-based for tic management and can be combined with any of the pharmacologic strategies above. CBIT is discussed in its own section below.

The Patient and Family Conversation

The conversation with a family weighing stimulant treatment for a child with tics has a predictable arc, and it benefits from a predictable structure.

I begin by asking what they have already been told. Almost always, someone — a previous clinician, a relative, an article — has told them that stimulants will worsen their child's tics. The fear is concrete and the source is often identifiable. Naming the source helps to disentangle clinical evidence from received wisdom.

Next, I explain the historical contraindication and where it came from: case reports, mechanistic reasoning, and FDA labeling decisions from the 1970s and 1980s. I make clear that these were reasonable inferences from the data available at the time, not malpractice or carelessness. The historical contraindication had a basis. It just turns out to have been wrong as a population-level rule.

I then summarize the modern evidence: Cohen 2015 meta-analysis showing no aggregate tic worsening across more than 2,000 children, TACT trial showing that methylphenidate plus clonidine produces the best outcomes for both ADHD and tics, current guideline endorsements from ESSTS, AACAP, and AAN. Families respond well to specifics — names of trials, numbers of patients, names of guideline bodies. Vague reassurance ("the new data don't really support that anymore") does not address the fear; specifics do.

I then turn to the individual question: in this specific child, given this specific severity of ADHD and this specific severity of tics, what do we want to try first, and how will we know whether it is working? I lay out the monitoring plan. I make clear that if tics worsen meaningfully and persistently after starting a medication, we will adjust — including switching agents or formulations — rather than abandoning ADHD treatment. The family's veto power is preserved throughout: nothing happens that they have not agreed to.

For some families, the conversation ends with a decision to start a stimulant. For others, it ends with a decision to start with guanfacine or clonidine and reassess. Both are evidence-supported. The single outcome that is not supported by evidence is to leave the ADHD untreated because of the tics. Whatever path the family chooses, it should not be that one.

Comorbid OCD: The "Tourette Plus" Presentation

A subset of patients with ADHD plus tic disorders also have obsessive-compulsive disorder. This triad — ADHD + Tourette + OCD — is sometimes referred to clinically as the "Tourette Plus" presentation. The conditions share genetic substrate (the same underlying neurodevelopmental architecture appears across all three) and frequently co-emerge during childhood and early adolescence.

Treatment of Tourette Plus is layered. The ADHD component is treated as discussed above — stimulants are not contraindicated by the tic or OCD diagnosis. The OCD component is typically treated with a selective serotonin reuptake inhibitor (often higher doses than for depression alone), exposure and response prevention (ERP) therapy as the evidence-based behavioral treatment, or both. The tic component may respond to alpha-2 agonists as already discussed, to CBIT, or in severe cases to an antipsychotic.

A clinically important nuance: in Tourette Plus, the patient's compulsive-symmetry symptoms may overlap with complex tics, and the differential between an obsessive-compulsive ritual and a complex motor tic can be genuinely difficult. The presence or absence of the premonitory urge, the cognitive content of the behavior (intrusive thoughts versus tension-release urge), and the patient's phenomenological description help to distinguish them. For overlapping presentations of attentional and obsessive-compulsive symptoms, see the discussion of OCD and ADHD as well as ADHD and anxiety.

Stimulant use in OCD-plus-ADHD has been an area of clinical caution because of concerns that stimulants could exacerbate obsessive-compulsive symptoms. The empirical evidence here is mixed and individualized; in practice, when OCD is the leading impairment, the SSRI is often started first and stabilized, then the stimulant is added if ADHD symptoms remain prominent. The combination is well tolerated in most patients.

Comprehensive Behavioral Intervention for Tics (CBIT)

No discussion of tic disorders is complete without CBIT. Comprehensive Behavioral Intervention for Tics is a manualized behavioral therapy that combines habit reversal training, function-based assessment, and relaxation training. The pivotal trial — Piacentini and colleagues in the Journal of the American Medical Association in 2010 — demonstrated that CBIT produced significant tic reduction compared with supportive therapy, with effect sizes comparable to those of pharmacologic agents.

The core of CBIT is habit reversal training: the patient learns to detect the premonitory urge that precedes a tic and to perform a competing response (an incompatible motor or behavioral action) that prevents the tic from occurring. With practice, the urge habituates and the tic frequency decreases. The therapy is typically delivered over 8 to 10 sessions and is appropriate from approximately age 9 or 10 upward, when the cognitive prerequisites are reliably present.

CBIT is recommended as first-line by the AAN guideline for tic disorders. It does not replace pharmacotherapy when tics are severe, but it is a valuable parallel intervention and is sometimes sufficient as monotherapy for mild-to-moderate tic presentations. The main practical barrier to CBIT is access — relatively few clinicians are formally trained — but availability has expanded over the past decade and telehealth-delivered CBIT has been studied with favorable results.

In the context of ADHD-plus-tics, CBIT can be combined with any of the pharmacologic strategies above. A typical optimized treatment plan for a child with significant ADHD and moderate Tourette syndrome might include a stimulant or alpha-2 agonist for ADHD, CBIT for tic management, and supportive school accommodations for both domains.

Putting It Together: The Modern Default

The accumulation of evidence over the past two decades has moved the field from "stimulants are contraindicated in Tourette" to "stimulants are one of several appropriate options for ADHD in the context of tics." This is not a minor change in framing. It is a fundamental reorientation of how clinicians should approach the comorbid presentation.

In practical terms, the modern default for a child or adolescent presenting with ADHD plus mild-to-moderate tics looks something like this: treat the ADHD with the agent best matched to the clinical picture — including stimulants — monitor tics during titration without expecting them to worsen, consider an alpha-2 agonist as combination or alternative therapy when tics are prominent, refer to CBIT when tic-focused behavioral therapy is needed, and reserve antipsychotics for tic severity that has not responded to first-line measures. Untreated ADHD is the option without empirical support.

The families I see who arrive having been refused stimulant treatment for years because of mild tics typically present with an accumulation of secondary harms from untreated ADHD: academic underperformance, low self-esteem, family conflict, and emotional dysregulation. None of those harms is intrinsic to the tic disorder. They are the cost of the historical contraindication outliving its evidence base. For the longer-term picture of why ADHD treatment matters, see adverse outcomes of untreated ADHD, medication tolerance over time, and the broader review of parenting with ADHD.

The stimulant-and-tics question is, in my judgment, the most consequential teaching reversal in pediatric ADHD pharmacology of the last twenty years. It is also one of the most under-disseminated. The trial data are clear. The guidelines are aligned. The clinical practice, in too many cases, has not caught up.

Frequently Asked Questions

Will stimulants cause my child's tics to worsen?

On aggregate, the evidence indicates no. The Cohen et al. 2015 meta-analysis of 22 controlled studies including more than 2,000 children found no statistically significant increase in tic severity in stimulant-treated groups compared with placebo. A subset of individual patients may experience transient tic exacerbation that typically resolves with dose adjustment, formulation change, or watchful waiting. Tics also fluctuate naturalistically, which can produce the appearance of medication effects that would have occurred without treatment.

What is the difference between a tic and a habit?

A tic is a sudden, rapid, recurrent, non-rhythmic motor movement or vocalization preceded by a premonitory urge — a sensation of tension that is released by the tic. Tics can be briefly suppressed but tend to rebound. Habits are learned behaviors without the premonitory urge and under more volitional control. The premonitory urge, the suppression-rebound pattern, and typical onset between ages 4 and 8 distinguish tics from habits. CBIT, the evidence-based behavioral treatment for tics, leverages the premonitory urge as its therapeutic target.

Should ADHD with tics be treated by neurology or psychiatry?

Both are appropriate. The historical division of labor — neurology for tics, psychiatry for ADHD — has blurred, and both specialties now train clinicians to manage comorbid presentations. For tic-predominant cases with movement disorder severity, pediatric neurology with movement disorders expertise may be optimal. For ADHD-predominant cases with mild-to-moderate tics, child and adolescent psychiatry typically provides comprehensive care. The clinician's comfort with both conditions matters more than their specialty label.

Are tic-specific medications addictive or dangerous in children?

The medications used specifically for tics — alpha-2 agonists (guanfacine, clonidine) and antipsychotics (aripiprazole, risperidone, less commonly haloperidol or pimozide) — are not addictive. Alpha-2 agonists have well-characterized side effects (sedation, hypotension, dry mouth) that are typically manageable. Antipsychotics carry more substantial side effect burden including weight gain and metabolic effects and are reserved for impairing tic severity. None are controlled substances. Stimulants used for the ADHD component are Schedule II but have low addiction risk in pediatric ADHD when used as prescribed; for cardiovascular safety questions, see ADHD medications and cardiovascular safety and ADHD medication side effects.

If tics emerge after starting a stimulant, does that mean the stimulant caused them?

Not necessarily. Tic disorders typically emerge between ages 4 and 8, the same age range as ADHD diagnosis. Temporal coincidence does not establish causation. The Cohen meta-analysis and registry data do not support stimulants as a cause of new tic disorders at the population level. For an individual patient with new tics on a stimulant, options include continued observation for spontaneous resolution, dose reduction, formulation change, addition of an alpha-2 agonist, or transition to atomoxetine.

Does my child need to stop stimulants if tics get worse?

Not automatically. The first question is whether the tics are functionally impairing — interfering with school, peer relationships, or causing pain. Minor waxing that does not impair functioning often does not warrant medication change, particularly if ADHD treatment is producing meaningful benefit. Options short of discontinuation include dose reduction, switching stimulant class, adding guanfacine or clonidine, or transitioning to atomoxetine. Complete stimulant discontinuation is rarely necessary and leaves the child with untreated ADHD, which carries its own documented harms.

Primary Reference

Pivotal Meta-Analysis: Cohen SC, Mulqueen JM, Ferracioli-Oda E, Stuckelman ZD, Coughlin CG, Leckman JF, Bloch MH. Meta-Analysis: Risk of Tics Associated With Psychostimulant Use in Randomized, Placebo-Controlled Trials. Journal of the American Academy of Child and Adolescent Psychiatry. 2015;54(9):728-736.

Pivotal Trial: Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology. 2002;58(4):527-536.

Guideline Reference: Roessner V, Eichele H, Stern JS, et al. European clinical guidelines for Tourette syndrome and other tic disorders — version 2.0. European Child and Adolescent Psychiatry. (ESSTS multidisciplinary consensus.)

Additional reading: ADHD Guide | ADHD Medication Guide | Dr. Sultan's Publications | PubMed: ADHD, tics, stimulants

Further Reading